Načítá se...

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies

INTRODUCTION: Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first‐line vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Wiele, Andrew J., Bathala, Tharakeswara K., Hahn, Andrew W., Xiao, Lianchun, Duran, Munevver, Ross, Jeremy A., Jonasch, Eric, Shah, Amishi Y., Campbell, Matthew T., Msaouel, Pavlos, Tannir, Nizar M.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2021
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176993/
https://ncbi.nlm.nih.gov/pubmed/33792094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13770
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!